In vitro interactions of natural health products with P-glycoprotein (P-gp) and cytochrome P450 3A4 (CYP3A4): Relevance to HIV therapies
| dc.contributor.advisor | Arnason, J. T., | |
| dc.contributor.author | Budzinski, Jason William | |
| dc.date.accessioned | 2013-11-07T17:24:03Z | |
| dc.date.available | 2013-11-07T17:24:03Z | |
| dc.date.created | 2003 | |
| dc.date.issued | 2003 | |
| dc.degree.level | Masters | |
| dc.degree.name | M.Sc. | |
| dc.description.abstract | This thesis examines the mechanisms by which natural health products (NHP)s may affect drug disposition pathways. Adverse reactions from concomitant NHP-drug use may result from competing interactions at the level of the metabolic enzyme cytochrome P450 3A4 (CYP3A4) or the xenobiotic efflux pump P-glycoprotein (P-gp). NHPs and drugs relevant to HIV were assessed for their ability to affect these drug disposition pathways. NHP extracts were examined for their ability to inhibit CYP3A4 and stimulate P-gP ATPase. Goldenseal (GS) NHPs were the most inhibitory of CYP3A4; GS and milk thistle (MT) teas stimulated P-gp ATPase more than the positive control verapamil. GS and MT extracts, related phytochemicals, and several HIV drugs were screened for their ability to modulate CYP3A4 and P-gp ( ABCB1 gene product) expression in caco2 cell monolayers. ABCB1 expression did not change from control levels; CYP3A4 expression was more responsive, and thus a better marker for cellular response. | |
| dc.format.extent | 78 p. | |
| dc.identifier.citation | Source: Masters Abstracts International, Volume: 41-06, page: 1720. | |
| dc.identifier.uri | http://hdl.handle.net/10393/26361 | |
| dc.identifier.uri | http://dx.doi.org/10.20381/ruor-9581 | |
| dc.language.iso | en | |
| dc.publisher | University of Ottawa (Canada) | |
| dc.subject.classification | Health Sciences, Pharmacology. | |
| dc.subject.classification | Health Sciences, Nutrition. | |
| dc.title | In vitro interactions of natural health products with P-glycoprotein (P-gp) and cytochrome P450 3A4 (CYP3A4): Relevance to HIV therapies | |
| dc.type | Thesis |
Files
Original bundle
1 - 1 of 1
